



THERADIAG renews the Standby Equity Facility (SEF®) with Société Générale

Croissy-Beaubourg and Montpellier, November 20, 2015 – Theradiag (ISIN: FRO004197747, Ticker: ALTER), a company specializing in theranostics and *in vitro* diagnostics, announces that it has renewed the Standby Equity Facility (SEF®) arranged with Société Générale, as approved by the shareholders' annual meeting of April 16, 2015.

Michel Finance, Chief Executive Officer of Theradiag, comments: "We have used the entirety of the previous SEF® set up with Société Générale. Its proceeds have allowed us to prepare the development in the USA of our LISA TRACKER portfolio, while limiting any dilution for our shareholders. We have decided to renew this SEF®, to further support our international activities specifically in order to develop new innovative products in collaboration with our Chinese partner HOB Biotech, while preserving our financial structure thanks to a limited discount".

Under the terms of the new SEF®, Société Générale has committed to subscribe to successive capital increases, issued by tranches over the next 24 months, within the global limit of 550,000 shares, i.e. 9.67% of the number of shares currently outstanding, all in compliance with laws and regulations, particularly regarding limitation as to the issuance of new shares under Article L. 225-136 of the *French Commercial Code*.

For each tranche, the issuance price will reflect the volume-weighted average price of shares for the three trading days immediately preceding the issue date, minus a discount of no more than 5%. This discount will enable Société Générale to instantly underwrite the shares despite possible market volatility. Acting as financial intermediary, Société Générale has no intention to remain a shareholder of the Company.

Should the entire standby equity facility be drawn down¹, a shareholder currently owning 1.0% of the company's share capital would see his or her share ownership reduced to 0.91%².

About Theradiag

Capitalizing on its expertise in the distribution, development and manufacturing of *in vitro* diagnostic tests, Theradiag innovates and develops theranostics tests (combining treatment and diagnosis) that measure the efficiency of biotherapies in the treatment of autoimmune diseases, cancer and AIDS. Theradiag notably markets the Lisa Tracker® range (CE marked), which is a comprehensive multiparameter theranostic solution for patients with autoimmune diseases treated with biotherapies. With its subsidiary Prestizia, Theradiag is developing new biomarkers based on microRNAs for the diagnosis and monitoring of rectal cancer, autoimmune and inflammatory diseases and HIV/AIDS. Theradiag is thus participating in the development of customized treatment, which favors the individualization of treatments, the evaluation of their efficacy and the prevention of drug resistance. The Company is based in Marne-la-Vallée, near Paris, and in Montpellier, and has over 75 employees.

¹ Leading to the issuance of 550,000 new shares

² Based on the non-fully diluted number of shares currently outstanding, i.e 5,688,822



For more information about Theradiag, please visit our website: www.theradiag.com



Theradiag

Investor Relations

Fabienne François

CFO

+33 1 64 62 10 12

contact@theradiag.com

NewCap

Financial communications /

Investor relations

Valentine Brouhot /

Pierre Laurent

+33 1 44 71 94 94

theradiag@newcap.fr

Alize RP

Press

Caroline Carmagnol /

Florence Portejoie

+33 1 44 54 36 64

theradiag@alizerp.com